Advertisement
Advertisement
CRBP
Corbus Pharmaceuticals Holdings, Inc.
3.07
USDSponsored
+0.21
+7.34%
Nov 06, 15:59 UTC -5
Closed
After-Market
3.07
0.00
0.00%
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Earnings
CRBP Earnings Reports
Positive Surprise Ratio
CRBP beat 23 of 43 last estimates.
53%
Next Report
Tomorrow
Date of Next Report
Nov 10, 2026
Estimate for Q3 26 (Revenue/ EPS)
$1.27M
/-$1.23
Implied change from Q2 26 (Revenue/ EPS)
--
/-32.04%
Implied change from Q3 25 (Revenue/ EPS)
--
/-35.26%
Corbus Pharmaceuticals Holdings, Inc. earnings per share and revenue
On Aug 06, 2026, CRBP reported earnings of -1.81 USD per share (EPS) for Q2 26, missing the estimate of -1.28 USD, resulting in a -41.05% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +1.78% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 7 analysts forecast an EPS of -1.23 USD, with revenue projected to reach 1.27 million USD, implying an decrease of -32.04% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Aclaris Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.12
Surprise
+28.49%
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.25
Surprise
-40.06%
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Dyne Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.92
Actual
-$1.06
Surprise
-15.57%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
Aldeyra Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+37.43%
Lipocine Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.08
Surprise
+77.91%
FAQ
What were Corbus Pharmaceuticals Holdings, Inc.'s earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Corbus Pharmaceuticals Holdings, Inc. reported EPS of -$1.81, missing estimates by -41.05%, and revenue of $0.00, 0% as expectations.
How did the market react to Corbus Pharmaceuticals Holdings, Inc.'s Q2 2026 earnings?
The stock price moved up 1.78%, changed from $9.57 before the earnings release to $9.74 the day after.
When is Corbus Pharmaceuticals Holdings, Inc. expected to report next?
The next earning report is scheduled for Nov 10, 2026.
What are the forecasts for Corbus Pharmaceuticals Holdings, Inc.'s next earnings report?
Based on 7
analysts, Corbus Pharmaceuticals Holdings, Inc. is expected to report EPS of -$1.23 and revenue of $1.27M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.